Controversial US-backed vaccine trial in African newborns halted

A US-backed vaccine trial for newborns in Guinea-Bissau has been halted due to lack of necessary governmental approval. This decision comes after the study drew global backlash, sparking concerns about the ethics of conducting medical research in vulnerable populations. The halt of the trial is significant because it highlights the importance of ensuring that medical research is conducted with the necessary approvals and safeguards in place to protect participants, particularly in low-income countries. The outcome may also have implications for future medical research collaborations between t…

Why it matters

The hepatitis B vaccine trial in African newborns was halted due to global backlash. This decision may impact the development of vaccines and public health initiatives in the region.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Guardian. For information only — not financial advice.